Scott Gottlieb, MD, acknowledged that hospitals have not traditionally been innovative in terms of service, but that they have been able to adopt innovations rapidly. It’s just that these innovations have come from other places.
John L. Fox, MD, MHA, emphasized his preferences for accountable care organizations (ACOs) due to their purpose of taking accountability for the management of the health of a population. In his eyes, the point of a bundle is undermined. “Where bundles, I think, work best is where there isn’t a lot of preference sensitive or physician-driven utilization… I think those make perfect sense because you can still manage the health of that isolated population without a lot of demand-driven use,” Dr Fox stated.
Dr Gottlieb also wants to push oncology bundles where it might make sense to do so; however, while Dr Patel thought bundling is possible for oncologists, but that it will take time to implement.
Ted Okon said that while there are areas where bundling makes sense—like with MD Anderson’s head and neck bundles—Medicare doesn’t view it as such. The Medicare side is usually black-and-white, and they don’t’ have the ability to selectively bundle, Okon said. With cancer, you would need to create a bundle for every type and iteration and he doesn’t see that as happening anytime soon.
HIVconsvX Vaccine Shows Safety, Immune Response in People on ART
March 10th 2025This research on a T-cell–targeting vaccines in HIV has implications for future study design to incorporate consideration of age and years on antiretroviral therapy (ART) to evaluate the level of immune reconstitution.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Ruxolitinib Cream Shows Long-Term Safety in AD, Potential for PN Treatment
March 8th 2025Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream (Opzelura; Incyte) in atopic dermatitis (AD), while late-breaking research highlighted its potential efficacy in prurigo nodularis (PN).
Read More